Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms GIMEMA-ERIC
- 12 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 12 Oct 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.
- 12 Oct 2018 Planned initiation date changed from 1 Jul 2018 to 1 Dec 2018.